121843-50-3

Upstream product

• 286-20-4 cyclohexane-1,2-epoxide 
• 69420-67-3 (+/-)-trans-[2-(pyrrolidinyl)]cyclohexanol 
• 137858-60-7 2-(N-t-butyloxycarbonyl-N-methylamino)cyclohexanone 
• 20431-81-6 rac-trans-2-methylamino-cyclohexanol 
• 130993-58-7 Methanesulfonic acid (1R,2R)-2-pyrrolidin-1-yl-cyclohexyl ester 
• 74-89-5 methylamine 
• 123-75-1 pyrrolidine 
• 51066-08-1 7-methyl-7-azabicyclo[4.1.0]heptane 
• 118768-63-1 trans-2-(N-pyrrolidinyl)cyclohexylamine 
• 109-94-4 formic acid ethyl ester 
• 133488-94-5 (+/-)-cis-2-(1-pyrrolidinyl)-N-benzoylcyclohexylamine 
• 133575-74-3 (1R,2S)-2-(pyrrolidin-1-yl)cyclohexanamine 
• 133488-96-7 (+/-)-cis-2-(1-pyrrolidinyl)cyclohexylamine 
• 137858-58-3 2-benzamidocyclohexanone 

Downstream Products

• 130553-27-4 2-(4-Chloro-phenyl)-N-methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 130553-78-5 N-Methyl-N-((1S,2R)-2-pyrrolidin-1-yl-cyclohexyl)-nicotinamide 
• 130553-24-1 (+/-)-cis-2-chloro-N-methyl-N-<2-(1-pyrrolidinyl)cyclohexyl>benzeneacetamide 
• 130553-33-2 2-(4-Methoxy-phenyl)-N-methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 130553-74-1 N-Methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-2-thiophen-3-yl-acetamide 
• 99239-28-8 2-(2,4-Dichloro-phenoxy)-N-methyl-N-((1S,2R)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 130553-49-0 N-Methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-3-(3,4,5-trimethoxy-phenyl)-propionamide 
• 130553-91-2 N-Methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide; hydrobromide 
• 125073-05-4 N-Methyl-2-(4-nitro-phenyl)-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 99239-25-5 2-(2,3-Dichloro-phenoxy)-N-methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 
• 130553-57-0 N-Methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-2-(2,4,5-trichloro-phenoxy)-acetamide 
• 130553-83-2 (E)-3-(3,4-Dichloro-phenyl)-N-methyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acrylamide 
• 130553-71-8 (E)-N-Methyl-3-phenyl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acrylamide; hydrochloride 
• 130553-61-6 N-Methyl-2-naphthalen-2-yl-N-((1R,2S)-2-pyrrolidin-1-yl-cyclohexyl)-acetamide 

Relevant academic research and scientific papers

Optimisation of the Anti-Trypanosoma brucei Activity of the Opioid Agonist U50488

Screening of the Sigma-Aldrich Library of Pharmacologically Active Compounds (LOPAC) against cultured Trypanosoma brucei, the causative agent of African sleeping sickness, resulted in the identification of a number of compounds with selective antiproliferative activity over mammalian cells. These included (+)-(1R,2R)-U50488, a weak opioid agonist with an EC50 value of 59nM as determined in our T.brucei invitro assay reported previously. This paper describes the modification of key structural elements of U50488 to investigate structure-activity relationships (SAR) and to optimise the antiproliferative activity and pharmacokinetic properties of this compound.

NITROGEN-CONTAINING CYCLOHETERO CYCLOALKYLAMINOARYL DERIVATIVES FOR CNS DISORDERS

Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders, convulsions and parkinsonism. Compounds of particular interest are of the formula STR1 wherein R 1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms and loweralkenylloweralkyl; wherein each of R 2 and R 3 is independently selected from hydrido and loweralkyl; wherein each of R 4 through R 7, R 10 and R 11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders

Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders and convulsions. Compounds of particular interest are of the formula STR1 wherein R1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms, and loweralkenylloweralkyl; wherein each of R2 and R3 is independently selected from hydrido and loweralkyl; wherein each of R4 through R7, R10 and R11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

N-Methyl-N--1-phenylcyclopropanecarboxylic amides - analogs of U50488 with much reduced opiate affinity and loss of κ-selectivity

(+/-)-N-methyl-N--1-phenylcyclopropanecarboxylic amide (1) and its dichloro analog (2) were synthesized.Compounds 1 and 2 are related to the κ-selective opiate U-50488 in that the benzylic methylene moiety in U-50488 has been replaced by a cyclopropane ring.As compared to U-50488, a 600-fold reduction in kappa-affinity was observed with these 2 compounds; while the reduction in μ-affinity was less than 2-fold.Unlike U-50488, 1 and 2 also show measurable δ-binding.To explain the observed anomaly, the steric interaction between the N-methyl group and the cyclopropane ring and the tendency of the cyclopropane ring to conjugate with the neighboring phenyl group, both affecting the accessible conformations of the amide side chains of 1 and 2, are cosidered important factors.

A PRACTICAL SYNTHESIS, OPTICAL RESOLUTION AND DETERMINATION OF ABSOLUTE CONFIGURATION OF ENANTIOMERICALLY PURE 1S,2R-(+)- AND 1R,2S-(-)-CIS-2-(1-PYRROLIDINYL)CYCLOHEXYLAMINES: IMPORTANT PRECURSORS FOR A NEW CLASS OF SIGMA-RECEPTOR LIGANDS AND ANTICONVULSANT DRUGS

Enantiomerically pure (+)- and (-)-cis-2-(1-pyrrolidinyl)cylohehexylamines ((+)- and (-)-4) were prepared starting with (+/-)-trans-2-aminocyclohexanol ((+/-)-5).The key step in the generation of the cis stereochemistry of (+)- and (-)-4 empolyed catalytic hydrogenation of the enamine mixture generated from condensation of pyrrolidine with (+/-)-2-(benzamido)cyclohexanone ((+/-)-7).An efficient optical resolution of (+/-)-4 was achieved through two recrystallizations of the mandelate salts.The absolute configuration of (+)- and (-)-4 was assigned as 1S,2R and 1R,2S,respectively, based on conversion of (-)-4 to and comparison with the N-methyl derivative (-)-13 of known 1R,2S absolute configuration.

Alterations in the stereochemistry of the κ-selective opioid agonist U50,488 result in high-affinity σ ligands

The synthesis and in vitro σ receptor activity of the two diastereomers of U50,488 [(±)-2], namely (1R,2S)-(+)-cis-3,4-dichloro-N-methyl-N-[2-(1- pyrrolidinyl)cyclohexyl]benzeneacetamide [(+)-1], and (1S,2R)-(-)-cis-3,4-dichloro-N-methyl-N-[2-(1- pyrrolidinyl)cyclohexyl]benzeneacetamide [(-)-1], are described. (+)-1 and (-)-1 were synthesized from (±)-trans-N-methyl-2-aminocyclohexanol [(±)-3]. Pyridinium chlorochromate (PCC) oxidation of the N-t-Boc-protected derivative of (±)-3 afforded (±)-2-[N-[(tert-butyloxy)carbonyl]-N-methylamino]cyclohexanone [(±)-5]. The sequence of enamine formation with pyrrolidine, catalytic reduction, N-deprotection, and optical resolution afforded (1R,2R)-(-)-cis-2-pyrrolidinyl-N-methylcyclohexylamine [(-)-10] and (1S,2R)-(+)-cis-2-pyrrolidinyl-N-methylcyclohexylamine [(+)-10]. The optical purity (>99.5%) of (-)-10 and (+)-10 was determined by HPLC analysis of the diastereomeric ureas formed by reaction with optically pure (R)-α-methylbenzyl isocyanate. The absolute configuration of (-)-10 and (+)-10 was determined by single-crystal X-ray diffractometry of the bis-(R)-mandelate salt. Condensation of optically pure (-)-10 and (+)-10 with 3,4-dichlorophenylacetic acid furnished (+)-1 and (-)-1, respectively. Compounds (+)-1, (-)-1, (-)-2, and (+)-2 were compared for their binding affinities at κ opioid, σ, D2-dopamine, and phencyclidine (PCP) receptors in competitive binding assays using [3H]bremazocine ([3H]BREM) or [3H]U69,593, [3H]-(+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [[3H]-(+)-3-PPP], or [3H]-1,3-di(o-tolyl)guanidine ([3H]DTG), [3H]-(-)-sulpiride [[3H]-(-)-SULP], and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP), respectively. In the systems examined, (-)-2 exhibited the highest affinity for κ receptors, with a K(i) of 44 ± 8 nM. However, (-)-2 also showed moderate affinity for σ receptors, with a K(i) of 594 ± 3 nM [[3H]-(+)-3-PPP]. The (1R,2S)-(+)-enantiomer, (+)-2, had low affinity for both κ and σ receptors, exhibiting K(i) values of 1298 ± 49 nM at κ ([3H]BREM) and 1270 ± 168 nM at σ [[3H]-(+)-3-PPP]. In contrast, the chiral cis compounds (+)-1 and (-)-1 showed high affinity for σ receptors and negligible affinity for κ opioid receptors in the [3H]BREM assay. Compound (-)-1 exhibited a K(i) of 81 ± 13 nM at σ receptors [[3H]-(+)-3-PPP] and 250 ± 8 nM ([3H]DTG). The corresponding values for (+)-1 were 221 ± 36 nM [[3H]-(+)-3-PPP] and 118 ± 7 nM ([3H]DTG). Compounds (-)-2 and (+)-2 lacked affinity for D2-dopamine receptors. Compounds (+)-1 and (-)-1 bound only weakly to D2-dopamine receptors, displaying K(i) values of 14039 ± 1429 nM and 3762 ± 829 nM, respectively. All of the compounds lacked affinity for PCP receptors.

Highly selective κ-opioid analgesics. 2. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide derivatives

This paper describes the chemical synthesis and the development of structure-activity relationships (SAR) for the κ opioid receptor affinity and μ/κ opioid receptor selectivity of novel N-[(2-aminocyclohexyl)aryl]acetamide derivatives. The SAR of this series are investigated by consideration of structural modifications made to the aromatic moiety, the amide linkage, and cyclohexane and the pyrrolidine ring substituents of the prototype κ selective agonist, PD117302 (trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzo[b]thiophene-4-act etamide) (1). The κ and μ opioid receptor binding affinities of 23 novel compounds are reported. It is observed that optimal μ/κ receptor selectivity is obtained with a benzo[b]thiophene aromatic system attached via the C-4 position, which is discussed in terms of steric and electronic parameters. The amide linkage has been replaced with the reversed amide, an ester, an aminomethylene, a thioamide, and a secondary amide. The best of these isosteres is the N-methyl amide. Substitution of the pyrrolidine ring of PD117302 in the 3-position with a hydroxymethylene group increases the μ/κ selectivity compared to the unsubstituted compound, e.g. compound 14, trans-(±)-N-methyl-N-[2-[3-(hydroxymethyl)-1-pyrrolidinyl]cyclo-hexylt ]-4-benzo[b]furanacetamide monohydrochloride, μ/κ receptor selectivity = 244. The cis fused, 4,5 dimethyl ether substituted cyclohexane analogue trans-(±)-N-methyl-N-[4,5-dimethoxy-2-(1-pyrrolidinyl)cyclohexyl]-bent zo[b]thiophene-4-acetamide monohydrochloride (32) has high in vitro κ opioid receptor affinity (K(i) = 16 nM) and equipotent analgesic activity to morphine after iv administration in rats.